Corrigendum: Tranexamic acid in combination with vancomycin or gentamicin has a synergistic effect against staphylococci

In the published article, there were errors in Table 2 as published. The S. aureus MIC₅₀ fold reductions for gentamicin+TXA 50 mg/ml appeared as 5. This has been corrected to 1. The S. epidermidis MIC₅₀ fold reductions for gentamicin+TXA 10mg/ml appeared as 9. This has been corrected to 8. The corrected Table 2 and its caption appear below.

Table 2.

MIC₅₀ for vancomycin and gentamicin alone and in combination with TXA using the automatized turbidity method.

Treatment	S. aureus MIC50 (ranges) mg/L	MIC50 fold reductions (no.)	S. epidermidis MIC50 (ranges) mg/L	MIC50 fold reductions (no.)	Overall MIC50 (ranges) mg/L	MIC50 fold reductions (no.)
Vancomycin	4 (0.12–16)		16 (16–16)		8 (0.12–16)
Vancomycin+TXA 10 mg/ml	0.03 (0.03–0.06)	8	0.03 (0.03–0.03)	8	0.03 (0.03–0.06)	8
Vancomycin+TXA 50 mg/ml	0.12 (0.03–0.25)	1	8 (0.03–16)	1	4 (0.03–16)	1
Gentamicin	16 (0.06–32)		32 (32–32)		32 (0.06–32)
Gentamicin+TXA 10 mg/ml	0.06 (0.06–0.12)	7	0.12 (0.06–0.25)	8	0.12 (0.06–0.25)	8
Gentamicin+TXA 50 mg/ml	8 (0.06–32)	1	16 (0.06–32)	1	16 (0.06–32)	1

TXA, tranexamic acid; MIC, minimal inhibitory concentration.

The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.